Immunology · global
Clues to the immune attack in lupus: Abnormal RNA splicing generates neoantigens
Researchers identified novel peptides generated by abnormal splicing in patients’ neutrophils and confirmed that T cells and antibodies can recognize these sequences. But whether these neoantigens drive disease or are a consequence of inflammation remains a question that must be resolved before moving toward treatment.
Why does the immune system attack the body in people with lupus? Part of the answer may lie in the process by which cells make proteins. A study published in Nature on October 28 found that abnormal messenger RNA splicing in patients’ neutrophils generates unusual protein fragments; patients’ T cells and antibodies can indeed recognize these fragments. This offers a new clue to the targets of the immune attack, but does not yet establish where the disease begins.
The study was co-led by Tomas Mustelin of the University of Washington and Stephen Schoenberger of the La Jolla Institute for Immunology. The team focused on neutrophils: immune cells that normally help defend against infection and are also closely associated with inflammation in lupus. The researchers asked whether these cells produce neoantigens capable of eliciting responses from other immune cells.
RNA splicing is a normal step in the cellular processing of instructions for making proteins. It removes some sequences and joins the retained segments together. If joining occurs at abnormal sites, the resulting products may contain amino acid sequences absent from normal proteins. This study concerns abnormal RNA processing and cannot be directly interpreted as evidence of corresponding mutations in patients’ DNA.
The team analyzed neutrophils from 34 patients with systemic lupus erythematosus and detected this type of abnormal splicing in 33 of them, involving a total of 130 genes and 271 splicing events. These events were not observed in the study’s 20 healthy donors or 15 patients with rheumatoid arthritis. However, the combinations of abnormalities varied considerably among patients; they did not all share the same set of neoantigens.
The evidence also extended from RNA to immune recognition. Using mass spectrometry, the researchers identified 21 peptides derived from novel sequences on major histocompatibility complex (MHC) class I molecules in patient samples, showing that these fragments can indeed be presented. In cell culture experiments, patients’ T cells responded to the novel peptides; their serum also contained IgG antibodies that recognized the novel sequences, supporting the involvement of both T cells and B cells in the associated immune responses.
However, identifying neoantigens remains a step short of proving that they trigger lupus. In an explanation from the La Jolla Institute for Immunology, Schoenberger emphasized that neoantigens could be either a cause or a consequence of inflammation; neutrophils may be responding to an inflammatory environment that has already caused tissue damage. The differences observed between patients and controls in the study are also insufficient to establish that these splicing events occur only in lupus.
The findings provide more specific targets for further investigation: when abnormal splicing appears and how it contributes to ongoing immune responses. It has not yet been demonstrated that blocking these neoantigens can improve disease, nor has a test or treatment been established for clinical use. The study offers a testable clue to a disease mechanism; evidence of therapeutic efficacy must be obtained separately.